Guizhou Kekai Medicine Co., Ltd. announced that it will receive CNY 52,000,000 in an equity round of funding from existing investor, Guizhou Xinbang Pharmaceutical Co., Ltd. (SZSE:002390) on February 29, 2016. The investor will acquire 0.002% stake in the company through this transaction and will hold 99.983% stake upon completion. Pursuant to the transaction, the capital of the company will increase from CNY 411,454,810 to CNY 463,454,810.

The transaction was approved at the 11th meeting of the 6th directorate meeting of the investor and does not need the approval from the shareholders of the investor.